Medical Marijuana Workshop - Part 2/3 (Audio)
Channel: MAPS
Date: 10/01/2014

Listen to the full workshop at https://2013.psychedelicscience.org

Prominent experts will share the lessons they have learned about marijuana research methodology (such as dosing, self-titration, placebo doses, and outcome measures), discuss the differing effects of the two primary cannabinoids THC and CBD, examine the forces impeding government approval of medical marijuana research, explore the history of the medical marijuana movement in California from 1996 to the present, and discuss future possibilities for research. The implications of new data on the use of cannabis as a substitute for alcohol, illicit, and prescription drugs for the clinical application of medical marijuana will also be discussed.

Troy Dayton was formerly the Marijuana Policy Project's top fundraiser and lead liaison to the legal cannabis industry. He co-founded Students for Sensible Drug Policy (now on over 200 campuses), and helped launch and serve as the first sales director at Renewable Choice Energy (recently named the #1 green power provider by the EPA). He is a founding board member of the National Cannabis Industry Association and part of the leadership team at the Interchange Counseling Institute. Previously Troy also worked with MAPS as Director of Development. In his spare time Troy enjoys singing karaoke and planning and blogging about Burning Man.

Mimi Peleg earned her BA in Sociology from U.C. Berkeley in 1993 where she focused on quantification and organizational sociology. In Israel she has worked for both HP and Check Point in the field of security. She is currently a Contract CRA for the MAPS MDMA/PTSD study at Beer Yaakov and the Director of Large Scale Cannabis Training for MECHKAR, Arbarbanel Hospital Bat Yam. Prior to moving to Israel she held computing positions at the University of California, Santa Cruz and the Wo/Men's Alliance for Medical Marijuana. She is co-author (with the late Robert Anton Wilson) of Everything Is Under Control: Conspiracies, Cults, and Cover-Ups.

Alan Shackelford, MD, is a graduate of the University of Heidelberg School of Medicine in Heidelberg, Germany and completed his postgraduate medical training at Harvard Medical School. He has coauthored medical studies published in peer-reviewed medical journals and several book chapters. He has advised legislators in Colorado, Connecticut, and New York on the medical uses of cannabis, testified before state Senate and House committees on medical cannabis legislation and serves on the Colorado Department of Revenue Medical Marijuana Advisory Work Group. Dr. Shackelford is principal physician of Amarimed of Colorado, a medical practice devoted to the study and evaluation of cannabis as a medical treatment option, and of Harvard Park Health, a medical group developing behavioral medicine-based treatment protocols to address insomnia, obesity and tobacco use.